Ricardo Villalon
5PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 29, 2023
The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.Nigel P Murray, Ricardo Villalon, Socrates Aedo
|Feb 28, 2022
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.Nigel P Murray, Ricardo Villalon, Dan Hartmann
|Sep 02, 2021
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.Nigel P Murray, Ricardo Villalon, Dan Hartmann
|Aug 28, 2021
Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.Nigel P Murray, Ricardo Villalon, Shenda Orrego
|Nov 10, 2020
The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.Nigel P Murray, Ricardo Villalon, Shenda Orrego
Pageof 1
